IIBR reports says BriLife Vaccine has the potential to protect against Covid variants, including delta and Omicron

0 26

NRx Pharmaceuticals, on Thursday, has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine may produce effective levels of neutralizing antibody against the Omicron variant of the SARS-CoV-2 virus.

“We are enormously encouraged by the recent findings of the IIBR. At a time when the majority of western populations have been vaccinated with mRNA vaccines, there is a clear need for a booster vaccine that can broaden immunity against current and future variants of concern. The BriLife vaccine has now demonstrated potential to continue to evolve in a manner that has the potential to protect against variants that are not yet known, and is planned to be tested as a booster in a phase 2 trial that will include Israel and other partner countries,”

Prof. Jonathan Javitt, MD, MPH, CEO and Chairman of NRx

The company in its recent document claims that many of the mutations (alterations) that cause the Omicron variant spike protein to differ from the spike protein of the original SARS-CoV-2 virus that causes COVID-19 have been identified in the spike protein of the BriLife vaccine. This natural evolution of the BriLife vaccine suggests that the vaccine may continue to evolve to address future Variants of Concern (VOCs). 

The IIBR report concludes that, “Taken together, our data indicates that BriLife®-induced antibodies maintain neutralizing potential against all tested variants, and most importantly against delta, and the recently emerged omicron VOCs. We suggest that spontaneously-acquired mutations that occurred during BriLife® development and correspond to naturally-occurring mutations of SARSCoV-2 variants, may increase the potential of BriLife® to maintain effectiveness against current SARS-CoV-2 variants, and potentially against future VOCs.”

In contrast to the current mRNA vaccines and attenuated virus vaccines, the BriLife vaccine is a live, viral vector vaccine in which the spike protein of the SARS-CoV-2 virus has been added to a benign virus, called VSV. 

The IIBR report, based on blood samples (sera) of patients vaccinated during the phase 2 trial of the BriLife vaccine conducted in Israel, documents that 10 of 13 tested sera demonstrated clinically detectable levels of Omicron-neutralizing antibody.

Leave A Reply

Your email address will not be published.